This experiment investigates whether traumatic brain injury (TBI) is a causal risk factor for later AD development and the mechanisms involved. Epidemiology shows associations between moderate-severe TBI and increased AD risk, but causality and mechanisms remain unclear.
Research Question
AD Gap #18: What is the relationship between TBI and later AD?
Does TBI cause or accelerate AD pathology through specific mechanisms, and can post-TBI interventions reduce AD risk?
Hypothesis
Moderate-severe TBI triggers chronic pathophysiological changes that accelerate Aβ accumulation, tau phosphorylation, and neuroinflammation. The "one-hit" hypothesis suggests that TBI causes lasting blood-brain barrier damage and microglial priming that lowers the threshold for later AD pathogenesis.
Experimental Design
Model System
...
Pathway Diagram
Mermaid diagram (expand to render)
Overview
This experiment investigates whether traumatic brain injury (TBI) is a causal risk factor for later AD development and the mechanisms involved. Epidemiology shows associations between moderate-severe TBI and increased AD risk, but causality and mechanisms remain unclear.
Research Question
AD Gap #18: What is the relationship between TBI and later AD?
Does TBI cause or accelerate AD pathology through specific mechanisms, and can post-TBI interventions reduce AD risk?
Hypothesis
Moderate-severe TBI triggers chronic pathophysiological changes that accelerate Aβ accumulation, tau phosphorylation, and neuroinflammation. The "one-hit" hypothesis suggests that TBI causes lasting blood-brain barrier damage and microglial priming that lowers the threshold for later AD pathogenesis.
Experimental Design
Model System
Animal: Controlled cortical impact (CCI) model in APP/PS1 mice vs WT mice
Cellular: Neuronal and microglial cultures from TBI-conditioned media exposure
Human: Retrospective cohort of TBI patients with longitudinal biomarkers
Validation Protocol
Phase 1: Acute-Chronic TBI sequelae
CCI injury in APP/PS1 mice vs WT littermates
Longitudinal Aβ PET at 1, 3, 6, 12 months post-injury
CSF biomarkers: Aβ42, t-tau, p-tau181, NfL at each timepoint
Post-mortem: Aβ plaques, NFT, synaptic markers at 12 months
Phase 2: Mechanistic Pathways
Blood-brain barrier integrity: Evans blue leakage, IgG extravasation
Microglial priming: RNA-seq of hippocampus at acute (1 week) and chronic (6 mo) phases
Chronic inflammation: TSPO PET at multiple timepoints
Neuronal stress: ER stress markers, mitochondrial dysfunction
Phase 3: Human Validation
Retrospective cohort: TBI patients with stored plasma (n=500) vs age-matched controls
Plasma biomarkers: p-tau217, NfL, GFAP at 1, 5, 10+ years post-TBI
Brain imaging (subset): Amyloid PET, MRI for cortical thickness
Genetic stratification: APOE4 carriers vs non-carriers
Phase 4: Intervention Testing
Post-TBI anti-inflammatory treatment (minocycline, colchicine) in mice
Anti-Aβ antibody administration at 1 month post-CCI
Metabolic support (ketogenic diet, Rolipram) for BBB repair
Expected Outcomes
Quantify TBI-accelerated pathology: Expected 2-3x acceleration of Aβ and tau in APP/PS1 mice
Identify causal pathways: Microglial priming and BBB damage as key drivers
Human risk estimate: APOE4 carriers at highest risk (~3-4x increase)
Feasibility Assessment
| Factor | Rating | Notes | |--------|-------|-------| | Technical feasibility | 8/10 | CCI model well-established; requires longitudinal imaging | | Cost efficiency | 5/10 | Long follow-up increases cost significantly | | Timeline | 24 months | Mouse study (12 mo) + human validation (12 mo) | | Cross-Disease value | 6/10 | Relevance to CTE, post-stroke dementia |
The following diagram shows the key molecular relationships involving Traumatic Brain Injury and Alzheimer's Disease Relationship discovered through SciDEX knowledge graph analysis: